Federated Hermes Inc. Sells 601,995 Shares of Pfizer Inc. (NYSE:PFE)

Federated Hermes Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 4.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,391,622 shares of the biopharmaceutical company’s stock after selling 601,995 shares during the period. Pfizer makes up about 0.8% of Federated Hermes Inc.’s portfolio, making the stock its 15th biggest position. Federated Hermes Inc. owned about 0.25% of Pfizer worth $381,810,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. PSI Advisors LLC boosted its stake in Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC grew its holdings in Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. raised its position in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton lifted its stake in Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC boosted its position in shares of Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 401 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Trading Down 5.4 %

Shares of NYSE:PFE opened at $22.99 on Friday. The company has a market capitalization of $130.39 billion, a PE ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $22.95 and a 12-month high of $31.54. The business’s fifty day simple moving average is $25.87 and its 200-day simple moving average is $26.74.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PFE shares. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.